J.P. Morgan analyst Robbie Marcus has maintained their bullish stance on BSX stock, giving a Buy rating on September 12.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Robbie Marcus’s rating is based on Boston Scientific’s strong growth prospects and strategic initiatives. The company is expected to achieve double-digit revenue growth, driven by products like Farapulse and Watchman, which are showing significant market momentum. This growth is anticipated to lead to operating margin expansion and mid-teens earnings per share growth, supported by a shift towards higher-margin products.
Additionally, Boston Scientific’s robust pipeline, including opportunities in intravascular lithotripsy and renal denervation, is expected to sustain its growth trajectory. The company’s strategy of leveraging its venture capital portfolio for acquisitions further strengthens its position. These factors collectively reinforce the Buy rating as Boston Scientific is well-positioned to exceed conservative growth expectations and deliver strong financial performance.
In another report released on September 12, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $117.00 price target.